In brief

Nova Mentis proposes hydroxytyrosol produced without direct dependence on olive harvests, targeting healthy ageing, cardiovascular and cognitive health and beauty-from-within.

Polyphenol‑HT1 is hydroxytyrosol produced through a biotechnological process rather than conventional olive extraction. The manufacturer positions it as a high-purity source with greater batch-to-batch consistency.

The proposition addresses two important industrial variables: standardisation and continuity of supply. Reducing dependence on harvests may make specifications, volumes and costs more predictable, while the full impact of process design and production scale still requires assessment.

The launch does not demonstrate that fermentation origin delivers a superior clinical effect. B2B selection still requires identity, purity and impurity profiles, stability, regulatory documentation, substantiated sustainability data and bioavailability comparison under real conditions of use.

Why it matters

Fermentation, purity and an agriculturally less dependent supply can change cost, scalability and B2B positioning for polyphenols.

Evidence limit

This is an industrial launch and manufacturer information, not a new clinical study. It does not establish biological superiority over olive-derived hydroxytyrosol.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · Nova Mentis ↗